Use of circulating tumour DNA to characterise the mutational landscape of marginal zone lymphoma, monitor treatment response and detect emergence of resistance

使用循环肿瘤 DNA 来表征边缘区淋巴瘤的突变情况、监测治疗反应并检测耐药性的出现

• 批准号: nhmrc : GNT1151560
• 负责人: Dr Kah Lok Chan
• 金额: $ 12.64万
• 依托单位国家: 澳大利亚
• 项目类别: Postgraduate Scholarships
• 财政年份: 2018
• 资助国家: 澳大利亚
• 起止时间: 2018-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/use-circulating-tumour-emergence-resistance/1349000
• 关键词: Use; circulating; tumour; DNA; characterise

Marginal zone lymphoma (MZL) is a subtype of B-cell non-Hodgkin lymphoma for which the molecular drivers of disease are poorly understood. We hypothesise that circulating tumour DNA may be ideal for characterising the genetic mutations that underpin MZL, monitoring treatment response and detecting emergence of resistance. This non-invasive method of disease monitoring has the potential to transform management of cancers such as MZL, identify new treatment options and improve survival outcomes.

边缘带淋巴瘤(MZL)是B细胞非霍奇金淋巴瘤的一种亚型，其发病的分子机制尚不清楚。我们假设，循环肿瘤DNA可能是表征支撑MZL的基因突变、监测治疗反应和检测耐药出现的理想方法。这种非侵入性的疾病监测方法有可能改变对MZL等癌症的管理，确定新的治疗方案，并改善生存结果。